NAV

Clidinium

Identification

Summary

Clidiniumis a synthetic anticholinergic used to treat peptic ulcer disease, colicky abdominal pain, diverticulitis, and IBS.

Brand Names
Chlorax, Librax
Generic Name
Clidinium
DrugBank Accession Number
DB00771
Background

Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.

Type
Small Molecule
组
Approved
Structure
MOL SDF PDB SMILES InChI
Similar Structures
Weight
Average: 352.4467
Monoisotopic: 352.191268703
Chemical Formula
C22H26NO3
Synonyms
  • 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane
  • 3-hydroxy-1-methylquinuclidinium benzilate ester
  • Bromure de Clidinium
  • Bromuro de clidinio
  • Clidinii Bromidum
  • Clidinium bromid
  • N-methyl quinuclidinyl benzilate

Pharmacology

Indication

For the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.

Mechanism of action

Inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites primarily by inhibiting the M1 muscarinic receptors.

Target Actions Organism
AMuscarinic acetylcholine receptor M1
antagonist
 Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Signs of toxicity include confusion, paralytic ileus, urinary hesitancy/retention, and blurred vision.

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
1,2-Benzodiazepine 1, 2-Benzodiazepine中央紧张可能会增加s system depressant (CNS depressant) activities of Clidinium.
Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
Acetophenazine Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
Aclidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Aclidinium.
Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Clidinium.
Agomelatine Agomelatine可能增加中枢神经系统m depressant (CNS depressant) activities of Clidinium.
Alfentanil The risk or severity of adverse effects can be increased when Clidinium is combined with Alfentanil.
Alimemazine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Clidinium.
Almotriptan Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid alcohol. Ingesting alcohol may increase the CNS depressant effects of the combination product Chlordiazepoxide HCl and Clidinium Bromide.
  • Take before a meal.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
Ingredient UNII CAS InChI Key
Clidinium Bromide 91ZQW5JF1Z 3485-62-9 GKEGFOKQMZHVOW-UHFFFAOYSA-M
Product Images
International/Other Brands
Dolibrax (Roche)/Porsucon (Ying Yuan)/Quarzan (Roche)/Sedaspa (Hua Shin)
Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
APO-CHLORAX CAPSULE Clidinium Bromide(2.5 mg)+Chlordiazepoxide hydrochloride(5 mg) Capsule Oral PHARMAFORTE SINGAPORE PTE LTD 1989-06-07 Not applicable
CHLOBAX TABLET Clidinium Bromide(2.5 mg)+Chlordiazepoxide(5 mg) Tablet, sugar coated Oral BEACONS PHARMACEUTICALS PTE. LTD. 1996-04-19 Not applicable
Chlorax Clidinium Bromide(2.5 mg)+Chlordiazepoxide hydrochloride(5 mg) Capsule Oral Aa Pharma Inc 1984-12-31 Not applicable Canada flag
Chlordiazepoxide HCl and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Micro Labs Limited 2022-10-01 Not applicable US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral A-S Medication Solutions 2009-09-23 Not applicable US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Dr. Reddy's Laboratories Inc. 2021-05-10 Not applicable US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Sunrise Pharmaceutical, Inc. 2020-07-09 Not applicable US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 1/1)+Chlordiazepoxide(5 mg/1) Capsule Oral Xiromed, Llc 2021-04-05 Not applicable US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Chartwell Rx, Llc 2020-10-20 Not applicable US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Avera McKennan Hospital 2016-01-18 Not applicable US flag
Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Chlordiazepoxide Clidinium Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral River's Edge Pharmaceuticals, LLC 2009-06-02 2012-03-31 US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Av Kare, Inc. 2009-11-19 2011-12-01 US flag
Chlordiazepoxide Hydrochloride And Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Acella Pharmaceuticals, LLC 2011-05-26 2015-03-31 US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Physicians Total Care, Inc. 1996-06-20 2013-01-15 US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Macoven Pharmaceuticals 2011-05-04 2015-06-04 US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Av Kare, Inc. 2013-01-03 2013-11-04 US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Burel Pharmaceuticals, Llc 2016-04-15 2017-03-24 US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Bi-Coastal制药公司 2011-05-04 Not applicable US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral BI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY 2011-05-04 Not applicable US flag
Chlordiazepoxide Hydrochloride and Clidinium Bromide Clidinium Bromide(2.5 mg/1)+Chlordiazepoxide hydrochloride(5 mg/1) Capsule Oral Boca Pharmacal, Inc. 2009-11-19 2010-12-20 US flag

Categories

ATC Codes
A03CA02 — Clidinium and psycholeptics
Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Quinuclidines/Piperidines/Tetraalkylammonium salts/Tertiary alcohols/Carboxylic acid esters/Monocarboxylic acids and derivatives/Azacyclic compounds/Organopnictogen compounds/Organic salts/Organic oxides
show 5 more
Substituents
Alcohol/Amine/Aromatic alcohol/Aromatic heteropolycyclic compound/Azacycle/Carbonyl group/Carboxylic acid derivative/Carboxylic acid ester/Diphenylmethane/Hydrocarbon derivative
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
carboxylic ester, organic cation, quaternary ammonium ion (CHEBI:3743)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
BO76JF850N
CAS number
7020-55-5
InChI Key
HOOSGZJRQIVJSZ-NNBUQUNQSA-N
InChI
InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1/t17-,20?,23+
IUPAC Name
(1s,4s)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-1-azabicyclo[2.2.2]octan-1-ium
SMILES
C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1

References

Synthesis Reference

Sternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc.
General References
Not Available
Human Metabolome Database
HMDB0014909
KEGG Compound
C07853
PubChem Compound
2784
PubChem Substance
46507814
ChemSpider
26330531
BindingDB
50055977
RxNav
21232
ChEBI
3743
Therapeutic Targets Database
DAP001117
PharmGKB
PA164781044
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clidinium_bromide

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Not Available Unknown Status Treatment Chest Pain 1

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
Packagers
  • Avkare Incorporated
  • Boca Pharmacal
  • Breckenridge Pharmaceuticals
  • Bryant Ranch Prepack
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Excellium Pharmaceutical Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • KVK-Tech Inc.
  • Legacy Pharmaceuticals Packaging LLC
  • Macoven Pharmaceuticals LLC
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Oceanside Pharmaceuticals Incorporated
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Provident Pharmaceuticals LLC
  • Resource Optimization and Innovation LLC
  • River's Edge Pharmaceuticals
  • Southwood Pharmaceuticals
  • Veratex Corp.
Dosage Forms
Form Route Strength
Capsule Oral 5 mg
Tablet, sugar coated Oral 5 mg
Capsule Oral
Capsule, gelatin coated Oral
Tablet, film coated Oral
Tablet, coated Oral
Pill Oral
Tablet, sugar coated Oral
Tablet, film coated Oral
Prices
Unit description Cost Unit
Quarzan 5 mg capsule 0.3USD capsule
Quarzan 2.5 mg capsule 0.23USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Property Value Source
melting point (°C) 240-241 °C Sternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc.
Predicted Properties
Property Value Source
Water Solubility 0.000377 mg/mL ALOGPS
logP -0.5 ALOGPS
logP -1.1 ChemAxon
logS -6 ALOGPS
pKa (Strongest Acidic) 11.05 ChemAxon
pKa (Strongest Basic) -4.5 ChemAxon
Physiological Charge 1 ChemAxon
Hydrogen Acceptor Count 2 ChemAxon
Hydrogen Donor Count 1 ChemAxon
Polar Surface Area 46.53 Å2 ChemAxon
Rotatable Bond Count 5 ChemAxon
Refractivity 112.14 m3·mol-1 ChemAxon
Polarizability 38.79 Å3 ChemAxon
Number of Rings 4 ChemAxon
Bioavailability 1 ChemAxon
Rule of Five Yes ChemAxon
Ghose Filter No ChemAxon
Veber's Rule No ChemAxon
MDDR-like Rule No ChemAxon
Predicted ADMET Features
Property Value Probability
Human Intestinal Absorption - 0.9243
Blood Brain Barrier + 0.9142
Caco-2 permeable + 0.671
P-glycoprotein substrate Substrate 0.8526
P-glycoprotein inhibitor I Non-inhibitor 0.7661
P-glycoprotein inhibitor II Non-inhibitor 0.9576
Renal organic cation transporter Inhibitor 0.6314
CYP450 2C9 substrate Non-substrate 0.7781
CYP450 2D6 substrate Non-substrate 0.6956
CYP450 3A4 substrate Substrate 0.6095
CYP450 1A2 substrate Non-inhibitor 0.9528
CYP450 2C9 inhibitor Non-inhibitor 0.9459
CYP450 2D6 inhibitor Inhibitor 0.6154
CYP450 2C19 inhibitor Non-inhibitor 0.9577
CYP450 3A4 inhibitor Non-inhibitor 0.9504
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9889
Ames test Non AMES toxic 0.8557
Carcinogenicity Non-carcinogens 0.933
Biodegradation Ready biodegradable 0.7763
Rat acute toxicity 2.4948 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.8162
hERG inhibition (predictor II) Non-inhibitor 0.6539
ADMET data is predicted usingadmetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Spectrum Spectrum Type Splash Key
Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details 1.Muscarinic acetylcholine receptor M1
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Drug created at June 13, 2005 13:24 / Updated at January 02, 2022 11:57